Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| The presentation was really well received and clearly laid out the distinct benefits of our vaccine technology as well as the clinical experience and our complete responders in vitalized to an audience filled with the biggest names in our field, BioNTech, Moderna, Gridstone, Scorpion, Merck, J&J, Regeneron amongst others |
| The fact that we are seeing patients who are so refractory respond to a therapeutic modality like this gives us really good confidence |
| We’re very well evolved |
| I remain convinced that this technology will realize the real performance – sorry, the real promise, I should say, of therapeutic cancer vaccines |
| We can’t change the larger economic environment, but we can ensure that IMV is in the best position possible to capitalize on our clinical success |
| We know, for instance, it can traffic small molecules like STING in a way that mitigates to toxicity typical for this mechanism, enhancing its therapeutic potential |
| What you just mentioned in reference where the really exciting data for the RNA vaccines in a prophylactic or a pseudo-prophylactic setting in a patient setting where the patient does not have active disease and you are defeating its recurrence |
| So as we are thinking about building out supply for the clinical studies today, but then the extension trials that will be registrational, we’re in a very good position with respect to the supply of commercial product |
| It’s the promise of what DPX technology and DPX-enabled therapies can provide that drives what we do |
| This is why our data is so encouraging |
| Above all of this, though, we know that it enhances the utility of mRNA and peptide-based vaccine cancer |
| We are learning alongside renewed interest in this whole field of cancer vaccines that DPX-enabled therapies can drive confirmed clinical responses not seen with historical efforts |
| And so I think when we reflect on our data, when we continuously see shrinkage of advanced disease, not just in one disease setting, not just diffuse large B-cell lymphoma, but also metastatic bladder, also advanced metastatic ovarian cancer, gives great confidence that the way our drug works, the way it consistently and continuously feeds immune instruction into the immune system |
| So, everyone at IMV is excited |
| I look forward to presenting the full set of data for VITALIZE and AVALON soon, which we believe will drive meaningful value for IMV and enable multiple opportunities |
| Mindful of that ambition, let me highlight some of the positive validation we at IMV created in 2022 |
| And congrats on the progress, I mean it looks good |
| The way it enables priming of anticancer T-cells, wave after wave across time helps us to imagine how it is that we can be successful in shrinking preexisting advanced lesions when others have not been successful in that space |
| That’s remarkable in the cancer vaccine space |
| The whole field benefits from this type of peer validation |
| Andrew Hall And Brandon, just to sort of get to the center of the question, we are getting very positive feedback on the data from strategics from academics, from people that are close to the field |
| Our best responses, our complete responders show us the greatest percent of survivin-specific T-cells, and those T-cells persist where we have been able to look with longitudinal sampling |
| I love reading that our peers developing cancer vaccines are making a meaningful difference to patient outcomes in early and even pre-cancer settings |
| The fact that we have seen the same number of complete responses in the first handful of patients as we had seen for the whole SPiReL trial and those complete responses have been confirmed by at least two scans, one at 70 and one at 140 days is to say the least encouraging |
| The durability is really critically important |
| Kalos to IMV’s Board to validate and enhance the DPX platform for cancer treatments |
| And particularly in a space where in the early disease setting where you would expect to see a greater therapeutic effect, we are starting now to see with Merck, Moderna and others putting really good data into market |
| In our history of DPX-based research, we know that it enhances the therapeutic effect of many types of immune-educating cargo |
| It’s an interesting time in small-cap biotech, and we believe we are pointing the organization in the right direction by the evolution of data that we are creating as well as the exploration of things that we believe is strategically prudent |
| Jeremy Graff is a much better source for that information |
| Statement |
|---|
| Not surprisingly, these vaccines fail to provide clinical benefit |
| Capital is difficult to find and the negative pressure on small companies or small cap companies either |
| Simply put, these vaccines fail to shrink tumors |
| That said, the market conditions are difficult |
| In practice, this has proven to be very difficult |
| Factors we knew this years ago |
| Even though in VITALIZE, we had already seen the same number of CRs in the first handful of patients that we had seen in all of the SPiReL trial, there was a pronounced sell-off of IMV stock |
| We believe prior cancer vaccines have failed, because they do not and they cannot deliver the appropriate immune instruction exclusively to the right immune cells, cells we call antigen-presenting cells |
| While the share consolidation in December reduced their holding by 10:1 as it did for every IMV shareholder, including myself, this was not a reflection of significant selling as was misinterpreted by some |
| In the recent release of the data, there was some confusion as to how far progressed this trial is |
| I want to make sure we give everyone confidence that this wasn’t IMV sort of cherry picking and manipulating data, which is some of the concerns I know our shareholders express |
| So how is it that despite all of this, we have lost so much value in the capital markets, accelerated recently by the sell-off following the DLBCL data release? This is a question we have asked ourselves a lot recently |
| The challenge is, and everyone recognizes this, us included, it’s early |
| The challenge was that the science that is seminal to this understanding was not built in a way that was immediately obvious to those outside of the organization |
| I joined because of what I saw IMV could become, a platform technology that meaningfully delivers the biological promise of cancer vaccines is something we have dreamt of, but faced with constant historical failure though it was impossible |
| With respect to our annual financials, which you can view in detail on SEDAR, EDGAR or on our website, we ended the year with a net loss of $38 million compared to a net loss of $36.6 million in 2021 |
| All forward-looking statements are subject to risks and uncertainty that could cause actual results to differ materially |
| We’ve seen the capital availability for small cap companies being limited |
| I would happily speculate, but I am clearly not well educated enough to do that |
Please consider a small donation if you think this website provides you with relevant information